Reuters: Regulatory News: UPDATE 1-US FDA approves generic versions of Merck's Singulair

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

UPDATE 1-US FDA approves generic versions of Merck's Singulair Aug 3rd 2012, 20:07 Fri Aug 3, 2012 4:07pm EDT WASHINGTON Aug 3 (Reuters) - The U.S. Food and Drug Administration on Friday said it granted 10 drugmakers marketing approvals for the first generic forms of Singulair, the $5 billion-a-year asthma and allergy drug that is Merck & Co Inc's best-selling product. The drugmakers, whose cheaper versions of Singulair are expected to quickly steal two thirds of the branded product's sales, include Mylan Inc, Teva Pharmaceutical Industries Ltd and the Sandoz division of Novartis AG. Singulair, unlike most allergy drugs which block the protein histamine, instead blocks proteins called leukotrienes that cause inflammation. Merck is counting on its respected pipeline of experimental drugs to come through and help offset the vanishing Singulair sales. Over the next 18 months, Merck aims to seek six drug approvals, including marketing applications for new types of therapies for insomnia and osteoporosis. Shares of Merck were up 0.5 percent in late-afternoon trading, trailing a 1.3 percent advance for the Arca Pharmaceutical Index of large U.S. and European drugmakers.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions